A recent study found that nearly 15% of patients initiating human immunodeficiency virus preexposure prophylaxis (PrEP) had an alcohol use disorder (AUD) diagnosis within 6 months, with only a small proportion receiving FDA-approved treatment. The study also highlighted the underdiagnosis of AUD prior to PrEP initiation and undertreatment following initiation, emphasizing the need for improved screening and access to evidence-based treatments for AUD in this population.

Source: JAMA Network Open